Patient-derived xenografts (PDXs) and patient-derived organoids (PDOs) have been shown
to model clinical response to cancer therapy. However, it remains challenging to use these …

Intratumoral regulatory T (Treg) cell abundance associates with diminished antitumor
immunity and poor prognosis in human cancers. Recent work demonstrates that CD25, the …

Monoclonal antibodies (mAbs) are improving the quality of life for patients suffering from
serious diseases due to their high specificity for their target and low potential for off-target …

Antibody-based immunotherapy is a promising strategy for targeting chemoresistant
leukemic cells. However, classical antibody-based approaches are restricted to targeting …

T cell bispecific antibodies (TCBs) are the focus of intense development for cancer
immunotherapy. Recently, peptide-MHC (major histocompatibility complex)-targeted TCBs …

T-cell–redirecting therapies are promising new therapeutic options in the field of cancer
immunotherapy, but the development of these modalities is challenging. A commonly …

Background T cell engagers are bispecific antibodies recognizing, with one moiety, the
CD3ε chain of the T cell receptor and, with the other moiety, specific tumor surface antigens …

Selective binding of TCR-like antibodies that target a single tumour-specific peptide antigen
presented by human leukocyte antigens (HLA) is the absolute prerequisite for their …

Our bodies are home to individual-specific microbial ecosystems that have recently been
found to be modified by cancer immunotherapies. The interaction between the gut …

Background T cell bispecific antibodies (TCBs) are extremely potent T cell engagers,
harboring a 2+ 1 format with one binder to the CD3ε chain and two binders to specific tumor …